Cargando…
Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
Lyotropic liquid crystals result from the self-assembly process of amphiphilic molecules, such as lipids, into water, being organized in different mesophases. The non-lamellar formed mesophases, such as bicontinuous cubic (cubosomes) and inverse hexagonal (hexosomes), attract great scientific intere...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028109/ https://www.ncbi.nlm.nih.gov/pubmed/35455426 http://dx.doi.org/10.3390/ph15040429 |
_version_ | 1784691534747140096 |
---|---|
author | Chountoulesi, Maria Pispas, Stergios Tseti, Ioulia K. Demetzos, Costas |
author_facet | Chountoulesi, Maria Pispas, Stergios Tseti, Ioulia K. Demetzos, Costas |
author_sort | Chountoulesi, Maria |
collection | PubMed |
description | Lyotropic liquid crystals result from the self-assembly process of amphiphilic molecules, such as lipids, into water, being organized in different mesophases. The non-lamellar formed mesophases, such as bicontinuous cubic (cubosomes) and inverse hexagonal (hexosomes), attract great scientific interest in the field of pharmaceutical nanotechnology. In the present review, an overview of the engineering and characterization of non-lamellar lyotropic liquid crystalline nanosystems (LLCN) is provided, focusing on their advantages as drug delivery nanocarriers and innovative vaccine platforms. It is described that non-lamellar LLCN can be utilized as drug delivery nanosystems, as well as for protein, peptide, and nucleic acid delivery. They exhibit major advantages, including stimuli-responsive properties for the “on demand” drug release delivery and the ability for controlled release by manipulating their internal conformation properties and their administration by different routes. Moreover, non-lamellar LLCN exhibit unique adjuvant properties to activate the immune system, being ideal for the development of novel vaccines. This review outlines the recent advances in lipid-based liquid crystalline technology and highlights the unique features of such systems, with a hopeful scope to contribute to the rational design of future nanosystems. |
format | Online Article Text |
id | pubmed-9028109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90281092022-04-23 Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms Chountoulesi, Maria Pispas, Stergios Tseti, Ioulia K. Demetzos, Costas Pharmaceuticals (Basel) Review Lyotropic liquid crystals result from the self-assembly process of amphiphilic molecules, such as lipids, into water, being organized in different mesophases. The non-lamellar formed mesophases, such as bicontinuous cubic (cubosomes) and inverse hexagonal (hexosomes), attract great scientific interest in the field of pharmaceutical nanotechnology. In the present review, an overview of the engineering and characterization of non-lamellar lyotropic liquid crystalline nanosystems (LLCN) is provided, focusing on their advantages as drug delivery nanocarriers and innovative vaccine platforms. It is described that non-lamellar LLCN can be utilized as drug delivery nanosystems, as well as for protein, peptide, and nucleic acid delivery. They exhibit major advantages, including stimuli-responsive properties for the “on demand” drug release delivery and the ability for controlled release by manipulating their internal conformation properties and their administration by different routes. Moreover, non-lamellar LLCN exhibit unique adjuvant properties to activate the immune system, being ideal for the development of novel vaccines. This review outlines the recent advances in lipid-based liquid crystalline technology and highlights the unique features of such systems, with a hopeful scope to contribute to the rational design of future nanosystems. MDPI 2022-03-31 /pmc/articles/PMC9028109/ /pubmed/35455426 http://dx.doi.org/10.3390/ph15040429 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chountoulesi, Maria Pispas, Stergios Tseti, Ioulia K. Demetzos, Costas Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms |
title | Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms |
title_full | Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms |
title_fullStr | Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms |
title_full_unstemmed | Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms |
title_short | Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms |
title_sort | lyotropic liquid crystalline nanostructures as drug delivery systems and vaccine platforms |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028109/ https://www.ncbi.nlm.nih.gov/pubmed/35455426 http://dx.doi.org/10.3390/ph15040429 |
work_keys_str_mv | AT chountoulesimaria lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms AT pispasstergios lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms AT tsetiiouliak lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms AT demetzoscostas lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms |